Augustine Therapeutics SA
11.0 FTEThe score of Augustine Therapeutics shows with a free account.
See the score- Summary? / 5
- Balance sheet strength
- Liquidity
- Repayment capacity
- Profitability
- Trajectory
- Compliance and register
- Position in its sectorvs peers
- Supplier creditat 30 d
- Borrowing capacityborrowable
- Valuationcentral
Visible once signed in: create your account, the 14-day Pro trial is free.
Key figures 2025
Change 2022 → 2025: Equity +1369 % Total assets +1042 % Headcount (avg FTE) +400 %
Accounts of the company itself (not consolidated).
The full file covers 6 financial years; a free account shows 2. →Deterministic calculation on the filed accounts, no AI. Dispute the score or report an error
Augustine Therapeutics's annual accounts
Filed annual accounts
- Year ended 31 Dec 2025filed on 05 Jun 2026
- Year ended 31 Dec 2024filed on 21 May 2025
- Year ended 31 Dec 2023filed on 27 Jun 2024
- Year ended 31 Dec 2022filed on 29 Jun 2023
- Year ended 31 Dec 2021filed on 07 Jun 2022
Augustine Therapeutics's financial analysis
- Solvency93.8%sector median: 61.7%
- Current ratio
- Net margin
- ROE
- Financial debt / EBITDA
- Interest coverage
- Days sales outstanding (DSO)
Management and control of Augustine Therapeutics
10 active director(s) in the register.
and 4 more
Augustine Therapeutics's shareholders and holdings →Augustine Therapeutics's publications in the Belgian Gazette
Company number, VAT number and registered office
- Company number (CBE)
- 0722.705.230
- VAT number
- BE0722705230
- Peppol
- Registered · 0208:0722705230 · as of 10 Nov 2026
- Legal form
- SA
- Incorporated
- 13 Mar 2019
- Registered office
- 3001 Leuven
- Size
- Small · 11.0 FTE
- Latest accounts
- 2025 · filed on 05 Jun 2026
- Activity
- Research and experimental development on biotechnology (NACE 72101)
Augustine Therapeutics (SA) has been based in Leuven since 2019, active in: research and experimental development on biotechnology. For 2025, it reports a net loss of €14.8m and equity of €29.0m; its revenue is not published. With 11.0 full-time equivalents, it is a small enterprise by headcount. Its solvency stands at 93.8%, above the median of its sector (61.7%).
Companies similar to Augustine Therapeutics
Companies in the same business, of comparable size and area, outside its group.
- iTeos Belgium Research and experimental development on natural sciences and engineering Charleroi · balance sheet €46.3m
- Confo Therapeutics Research and experimental development on natural sciences and engineering Ghent · balance sheet €37.8m
- OSIVAX Belgique Research and experimental development on natural sciences and engineering Liège · balance sheet €17.0m
- The Akkermansia Company Research and experimental development on natural sciences and engineering Mont-Saint-Guibert · balance sheet €16.9m
- The Oncidium Foundation Research and experimental development on natural sciences and engineering Auderghem · balance sheet €60.5m
- AstriVax Therapeutics Research and experimental development on natural sciences and engineering Leuven · balance sheet €12.5m
- Biotalys Research and experimental development on natural sciences and engineering Ghent · balance sheet €16.3m
- Nanocyl Research and experimental development on natural sciences and engineering Sambreville · balance sheet €13.2m
Frequently asked questions about Augustine Therapeutics
What is the revenue of Augustine Therapeutics?
Augustine Therapeutics files its accounts in a format where revenue is optional: it is not published for 2025.
What is the VAT number of Augustine Therapeutics?
In Belgium, the VAT number is the company number prefixed with BE: BE0722705230 for Augustine Therapeutics, if the company is VAT-registered. Its company number (CBE) is 0722.705.230.
Where is the registered office of Augustine Therapeutics?
According to the CBE register, the registered office of Augustine Therapeutics is in 3001 Leuven.
What is the equity of Augustine Therapeutics?
At the close of the 2025 financial year, the equity of Augustine Therapeutics amounts to 28,979,107 €, a solvency of 93.8% of total assets.
How many people work at Augustine Therapeutics?
11.0 full-time equivalents on average according to the 2025 social balance sheet.
Who manages Augustine Therapeutics?
The register lists 10 active mandates at Augustine Therapeutics. Names and roles are in the full file, with the deeds published in the Belgian Gazette.
The full file of Augustine Therapeutics
Directors and mandates, ownership network, Gazette deeds, ten years of accounts and ratios, Excel export, and Idonis's analysis in one question.
Open the full file →